Metrics as of 10/17/2026, 08:47 AM (Berlin time), refresh in progress.
ADMA Biologics Stock
ADMA Biologics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Adam S. Grossman
- Employees
- 644
- Market cap
- $2.4 B
- IPO
- 17/10/2013
ADMA Biologics, Inc. is a biopharmaceutical company in the Healthcare sector that specializes in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. Founded in 2004, the company is headquartered in Ramsey, New Jersey. Its specialized products are engineered…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
ADMA Biologics stock: price history
1D
-0.5%
1W
+3.1%
1M
+20.0%
6M
-3.0%
YTD
-41.4%
1Y
-26.6%
2Y
-35.0%
5Y
+870.9%
10Y
+67.1%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~50% stronger price swings than usual
Ask the agents about ADMA Biologics
Analyst assessment of ADMA Biologics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$18.67
MEDIAN
US$18.00
PRICE TARGET HIGH
US$21.00
1
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 15/07/2026
ADMA Biologics stock metrics
P/E
14.83
P/B
5.97
EV/EBITDA
10.56
RETURN ON EQUITY
9.3%
NET MARGIN
30.4%
DEBT/EQUITY
0.5
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.0%
FLOAT SHARES
219,657,296
AVG. DAILY VOLUME (30D)
3,139,433
Insider transactions (SEC)
Kestenberg-Messina Kaitlin M.
Kohler Terry
Grossman Jerrold B
Grossman Jerrold B
Grossman Jerrold B
Institutional holders
Comparable stocks
Frequently asked questions about ADMA Biologics stock
What does ADMA Biologics do?
ADMA Biologics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Adam S. Grossman, the company employs around 644 people.
The IPO was on 17/10/2013; the stock trades on NASDAQ under the ticker ADMA.
What do analysts say about ADMA Biologics stock?
10 analysts rate the stock, the consensus is Buy (as of 15/07/2026).
The average price target is US$18.67, ranging from US$17.00 to US$21.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does ADMA Biologics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 50% stronger than usual.
Does ADMA Biologics pay a dividend?
No, ADMA Biologics currently does not pay a dividend.
Which stocks are comparable to ADMA Biologics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ADMA Biologics stock analyzed?
Clicking "Analyze stock" lets five strategies assess ADMA Biologics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.